David Close

David Close

AstraZeneca, Sweden - Södertälje / Sweden
Medical and Health Sciences / Immunology
AD Scientific Index ID: 4402441
-
person_outline David Close's MOST POPULAR ARTICLES
1-) Efficacy of B-cell–targeted therapy with rituximab in patients with rheumatoid arthritisJCW Edwards, L Szczepański, J Szechiński, A Filipowicz-Sosnowska, ...New England Journal of Medicine 350 (25), 2572-2581, 200432362004
2-) Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double‐blind, phase III studyEF Mysler, AJ Spindler, R Guzman, M Bijl, D Jayne, RA Furie, ...Arthritis & Rheumatism 65 (9), 2368-2379, 20132632013
3-) Matrix metalloproteinase inhibitors in rheumatic diseasesDR CloseAnnals of the rheumatic diseases 60 (suppl 3), iii62-iii67, 20011642001
4-) A randomised phase IIb study of mavrilimumab, a novel GM–CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritisGR Burmester, IB McInnes, J Kremer, P Miranda, M Korkosz, J Vencovsky, ...Annals of the Rheumatic Diseases 76 (6), 1020-1030, 20171452017
5-) A randomized phase II b study of mavrilimumab and golimumab in rheumatoid arthritisME Weinblatt, IB McInnes, JM Kremer, P Miranda, J Vencovsky, X Guo, ...Arthritis & rheumatology 70 (1), 49-59, 2018942018